Biochemical nature and cellular distribution of the paired immunoglobulin-like receptors, PIR-A and PIR-B

Hiromi Kubagawa, University of Alabama at Birmingham
Ching-Cheng Chen, University of Alabama at Birmingham
Le Hong Ho, Howard Hughes Medical Institute
Toshihide Shimada, University of Alabama at Birmingham
Lanier Gartland, Howard Hughes Medical Institute
Charles Mashburn, Howard Hughes Medical Institute
Takahiro Uehara, University of Alabama at Birmingham
Jeffrey V. Ravetch, Rockefeller University
Max Cooper, Emory University

Journal Title: Journal of Experimental Medicine
Volume: Volume 189, Number 2
Publisher: Rockefeller University Press | 1999-01-18, Pages 309-317
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1084/jem.189.2.309
Permanent URL: https://pid.emory.edu/ark:/25593/rqq32

Final published version: http://dx.doi.org/10.1084/jem.189.2.309

Copyright information:
© Rockefeller University Press.

Accessed September 20, 2019 9:03 PM EDT
Biochemical Nature and Cellular Distribution of the Paired Immunoglobulin-like Receptors, PIR-A and PIR-B

By Hiromi Kubagawa, Ching-Cheng Chen, Le Hong Ho, Toshihide Shimada, Lanier Gartland, Charles Mashburn, Takahiro Uehara, Jeffrey V. Ravetch, and Max D. Cooper

From the Division of Developmental and Clinical Immunology, Department of Pathology, Department of Microbiology, Department of Pediatrics, and Department of Medicine, University of Alabama at Birmingham, and the Howard Hughes Medical Institute, Birmingham, Alabama 35294; and the Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York 10021

Summary

PIR-A and PIR-B, paired immunoglobulin-like receptors encoded, respectively, by multiple Pira genes and a single Pirb gene in mice, are relatives of the human natural killer (NK) and Fc receptors. Monoclonal and polyclonal antibodies produced against a recombinant PIR protein identified cell surface glycoproteins of ~85 and ~120 kD on B cells, granulocytes, and macrophages. A disulfide-linked homodimer associated with the cell surface PIR molecules was identified as the Fc receptor common γ chain (FcRγc) chain. Whereas PIR-B fibroblast transfectants expressed cell surface molecules of ~120 kD, PIR-A transfectants expressed the ~85-kD molecules exclusively intracellularly; PIR-A and FcRγc cotransfectants expressed the PIR-A/FcRγc complex on their cell surface. Correspondingly, PIR-B was normally expressed on the cell surface of splenocytes from FcRγc<sup>−/−</sup> mice whereas PIR-A was not. Cell surface levels of PIR molecules on myeloid and B lineage cells increased with cellular differentiation and activation. Dendritic cells, monocytes/macrophages, and mast cells expressed the PIR molecules in varying levels, but T cells and NK cells did not. These experiments define the coordinate cellular expression of PIR-B, an inhibitory receptor, and PIR-A, an activating receptor; demonstrate the requirement of FcRγc chain association for cell surface PIR-A expression; and suggest that the level of FcRγc chain expression could differentially affect the PIR-A/PIR-B equilibrium in different cell lineages.

Key words: Fc receptor γ chain • activating receptor • inhibitory receptor • dendritic cells • innate immunity

The paired immunoglobulin-like receptors (PIR) PIR-A and PIR-B have been identified recently in mice on the basis of their homology with the human Fcα receptor (FcαR) (1, 2). PIR-A and PIR-B share sequence similarity with a gene family that includes human FcαR and killer inhibitory receptors (KIR), mouse gp49, bovine Fc receptor for IgG (FcγR), and the recently identified human Ig-like transcripts (ILT)/leukocyte Ig-like receptors (LIR)/monocyte/macrophage Ig-like receptors (MIR) (3–12). The Pira and Pirb genes are located on mouse chromosome 7 in a region syntenic with the human chromosome 19q13 region that contains the FcαR, KIR, and ILT/LIR/MIR genes (1, 4, 5, 9, 11–14). DNA sequences for PIR-A and PIR-B predict type I transmembrane proteins with similar ectodomains (>92% homology) each containing six Ig-like domains. However, PIR-A and PIR-B have distinctive membrane proximal, transmembrane, and cytoplasmic regions. The PIR-B protein, encoded by the Pirb gene (1, 13, 15), has a typical uncharged transmembrane region and a long cytoplasmic tail with multiple candidate immunoreceptor tyrosine-based inhibitory motifs (ITIMs). Recent studies have demonstrated the inhibitory function of the two most membrane-distal ITIM units in the PIR-B cyto-
plasmic region (16, 17). The PIR-B inhibitory function is mediated through ITIM recruitment of the protein tyrosine phosphatase SHP-1 (16, 17). Conversely, the predicted PIR–A protein has a short cytoplasmic tail and a charged arginine residue in its transmembrane region, suggesting possible association with transmembrane proteins containing immunoreceptor tyrosine-based activation motifs (ITAMs) to form a signal-transducing unit. In addition, the PIR–A receptors, which are encoded by multiple Pira genes, display sequence diversity in their extracellular regions.

In this study, monoclonal and polyclonal antibodies specific for common epitopes on PIR–A and PIR–B molecules were used to characterize these cell surface receptors and the cellular distribution of their expression in normal and Fc receptor common γ chain (FcRγc)-deficient mice. The results indicate an essential role for PIR–A association with the FcRγc for cell surface expression on B lineage, myeloid, and dendritic cells.

Materials and Methods

Cell Preparation. Bone marrow cells were isolated from the femur by flushing with media, and the myelocytes lysed in a 0.1 M ammonium chloride buffer solution at pH 7.4. Spilicocytes were prepared by splenic disruption, gentle teasing, and density gradient centrifugation over Lympholyte-M (Accurate Chemistry & Science Corp.). Splenic B cells were enriched by depletion of M ac-1- macrophages and granulocytes and of CD3+ T cells by a panning method (18). Granulocytes were isolated from peritoneal exudates induced by prior injection of 0.4% (wt/vol) calcium caseinate (Spectrum Quality Products, Inc.). Exudates induced by prior injection of 0.4% (wt/vol) calcium caseinate were centrifuged over Lympholyte® (Qiagen) which was used to transform B cells/sample and PIR–A or PIR–B transfected LTK cells (10) were lysed in 500 μl of lysis buffer (1% NP-40 in 150 mM NaCl/50 mM Tris-HCl, pH 7.5, containing 5 mM EDTA, 20 mM iodoacetamide, 0.1% sodium azide, 20 mM e- amino-caproic acid, antipain [2 μg/ml], leupeptin [1 μg/ml], soybean trypsin inhibitor [100 μg/ml], aproptin [2 μg/ml], 1 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride hydrochloride, chymostatin [2.5 μg/ml], and pepstatin [1 μg/ml]). A solid-phase immunosolization technique (SPIT) (22) was used to identify anti-PIR reactive molecules in cell lysates precleared by centrifugation. In brief, 96-well
plates were coated with goat antibodies to rat Ig and then with rat anti-PIR or isotype-matched control mAbs before incubation with cell lysates overnight at 4°C. After extensive washing, bound molecules were dissociated by addition of 2% SDS, resolved by SDS-PAGE, transferred onto nitrocellulose membranes by electrophoretic blotting, incubated sequentially with rabbit anti-PIR antiserum (1:2,000 dilution) and horseradish peroxidase-labeled goat anti-rabbit Ig antibody (0.25 μg/ml; Southern Biotechnology Associates), and visualized by enhanced chemiluminescence (Amersham Life Science). In other experiments, blotted membranes were incubated with rabbit antibodies against FcR γc (gift of Drs. Robert P. Kimberly and Jeffrey C. Edberg, University of Alabama at Birmingham, Birmingham, AL).

Immunoprecipitation of Cell Surface Proteins. Viable cells (~3 × 10⁷) were surface labeled with 1 mCi of Na¹²⁵I by the lactoperoxidase method (23) and solubilized in ~500 μl of 1% NP-40 or 1% digitonin lysis buffers. After centrifugation, iodinated PIR molecules were isolated by SPIT, separated on SDS-PAGE (8–15% acrylamide) under reducing and nonreducing conditions, and the dried gels exposed to x-ray films (24). Alternatively, isolated PIR molecules were analyzed by nonreducing/reducing diagonal SDS-PAGE (25). In other experiments, cell surface PIR molecules were digested with N-glycanase (Oxford Glycosciences) before SDS-PAGE analysis (24).

Immunofluorescence Analysis. Cells were incubated with aggregated human IgG to block FcγRs, then stained with PE-labeled anti-PIR mAbs and a combination of FITC-, Cyochrome (CY)-, allophycocyanin, or biotin-labeled mAbs specific for B220, CD19, CD21, CD23, CD43, or CD5 for B-lineage cells; CD3, CD4, or CD8 for T-lineage cells; Mac-1 (CD11b) or Gr-1 for myeloid lineage cells; DX5 antigen for pan NK cells; CD11c for dendritic cells, and Ter-119 for erythroid lineage cells (PharMingen). Other reagents included FITC-labeled goat anti-mouse μ chain antibody and isotype-matched control mAbs l-a-

Figure 1. Cell surface reactivity of the 6C1 anti-PIR mAb. Mouse LTK cells transfected with the empty vector (A), LTK cells transfected with the PIR-B expression vector (B), M1 myeloblastoid cells (C), and WEHI3 myeloid cells (D) were incubated with 6C1 rat anti-PIR mAb (shaded histogram) or an isotype-matched control mAb (open histogram), before developing with PE-labeled goat antibodies to rat Ig. The stained cells were analyzed by flow cytometry.

Figure 2. Analysis of cell surface and intracellular PIR molecules. Viable splenocytes from normal adult BALB/c mice were radiolabeled with Na¹²⁵I and solubilized in 0.5% NP-40. The clarified membrane lysates were incubated in wells precoated with 6C1 anti-PIR or an isotype-matched control mAb. The bound materials were resolved on SDS-PAGE using 10% acrylamide under nonreducing (not shown) and reducing conditions (A) or digested with or without N-glycanase before SDS-PAGE analysis (B). The same ~85 and ~125-kD PIR molecules were observed in splenocytes, purified splenic B cells, and granulocytes (C) as well as the X16C8.5 B cell and WEHI3 macrophage cell lines (D). In contrast, the 85-kD band was expressed by PIR-A transfected fibroblasts, while the ~120-kD band was expressed by the PIR-B transfactants (D). In the experiments shown in C and D, NP-40 lysates of splenocytes, purified B cells, granulocytes, the LTK cells transfected with empty vector or PIR-A or PIR-B expression vectors, the X16C8.5 B cell line, and the WEHI3 macrophage cell line were incubated in wells precoated with 6C1 anti-PIR mAb or isotype-matched control mAb (not shown). The bound PIR molecules were separated in SDS-PAGE under nonreducing conditions, transferred onto membranes, and identified with rabbit anti-PIR antiserum and enzyme-labeled goat anti-rabbit Ig antibody before visualization by enhanced chemiluminescence.
beled with PE, FITC, CY, or biotin (Southern Biotechnological Associates). Stained cells were analyzed with a FACScan® flow cytometry instrument (Becton Dickinson).

**Results**

Generation of Monoclonal and Polyclonal Anti-PIR Antibodies. Recombinant PIR protein containing the two NH₂-terminal Ig-like extracellular domains, EC1 and EC2, in the PIR-A1 molecule was produced in E. coli. The PIR-A1 EC1/EC2 recombinant protein was selected to immunize rats because of its sequence identity with PIR-B (1). 1 d before fusion of regional lymph node cells to produce hybridomas, the immunized rats were boosted with viable WEHI3 myeloid cells to enhance the possibility of obtaining antibodies that recognize epitopes on native PIR molecules. 33 hybridoma clones produced antibodies that reacted by ELISA with the recombinant PIR-A1 EC1/EC2 protein. Cell surface immunofluorescence analysis indicated that one of the antibodies, 6C1 (γ1κ), was reactive with PIR-B–transfected LTK fibroblasts and the WEHI3 myeloid cell line (Fig. 1). This mAb was unreactive with mock-transfected LTK fibroblasts and the M1 myeloblastoid cell line that lack PIR-A and PIR-B transcripts. Binding of the 6C1 antibody to the WEHI3 cells was inhibited by the recombinant PIR-A1 EC1/EC2 protein in a dose-dependent manner. The recombinant PIR-A1 EC1/EC2 protein was also used to produce a rabbit antiserum, the specificity of which was indicated by ELISA and by Western blot assays of the native PIR-A and PIR-B proteins described below.

Biochemical Characteristics of the PIR-A and PIR-B Molecules. When iodinated cell surface proteins on splenocytes, B cell lines, and macrophage cell lines were examined by SDS-PAGE, the anti-PIR antibodies identified two major species of ~85 and ~120 kD with minor bands of slightly lower molecular masses (Fig. 2 A). Slightly higher molecular masses were evident under reducing conditions, ~90 and ~125 kD, respectively, consistent with predicted intradisulfide linkages of the six Ig-like extracellular domains. N-glycanase treatment reduced their apparent molecular masses by 10–15 kD in keeping with the presence of five to six potential N-linked glycosylation sites in the PIR-A and PIR-B molecules (Fig. 2 B). Two-dimensional electrophoretic analysis under nonreducing and reducing conditions confirmed that the ~85 and ~120-kD proteins identified on splenocytes by the anti-PIR antibodies did not exist as covalently linked molecules (not shown). B cells purified from the spleen and granulocytes purified from peritoneal exudates also expressed ~85 and ~125-kD molecules (Fig. 2 C). These findings indicate that cell surface PIR molecules are glycoproteins of ~85 and ~120 kD, and that both molecular species are expressed by clonal B and myeloid cells.

Since the monoclonal and polyclonal antibodies recognize epitopes present on both PIR-A and PIR-B molecules, mouse LTK cells transfected either with PIR-A1 or PIR-B cDNAs were used for discrimination of the PIR molecules. A major band of ~120 kD, together with a faint band of ~97 kD, was immunoprecipitated by the 6C1 anti-PIR mAb from lysates of the PIR-B transfectants, and not from lysates of mock transfectants probed by immunoblotting with the rabbit anti-PIR antibodies (Fig. 2 C). Conversely, the anti-PIR mAb precipitated a major band of ~85 kD and a minor band of ~70 kD from cell lysates of the PIR-A1 transfectants. The two major bands of 85 and 120 kD were also identified by the 6C1 mAbs and the rabbit anti-PIR antibodies in normal splenocytes, B cell, and myeloid cell lines, all of which express Pira and Pirb.
PIR-A Association with FcRγc. The PIR-A protein has a short cytoplasmic tail without recognizable functional motifs, but the presence of a charged amino acid, arginine, in the transmembrane region suggested its potential association with another transmembrane protein (1). Inferential evidence in support of this possibility was provided by studies of the cell surface proteins expressed by PIR-A and PIR-B fibroblast transfectants. A major band of ~120 kD was identified on the cell surface of PIR-B transfected LTK cells by the 6C1 antibodies (not shown), whereas the ~85 and ~70-kD molecules expressed by PIR-A1 transfectants (see Fig. 2 C) were identified only intracellularly. Cell surface PIR-A molecules were not identified by the anti-PIR mAb on PIR-A transfectants, thereby implying that PIR-A requires companion molecules, not present in fibroblasts, to reach the cell surface. Accordingly, two-dimensional analysis of the proteins precipitated with the 6C1 anti-PIR antibody from iodinated cell surface proteins on splenocytes revealed an associated homodimer composed of relatively small disulfide-linked subunits (~10 kD, not shown). Immunoblots of the cell surface PIR complex separated under reducing conditions by SDS-PAGE identified these associated proteins as FcRγc (Fig. 3 B).

The requirement of FcRγc association for the cell surface expression of PIR-A was examined by fibroblast cotransfection experiments. While PIR-A producing transfectants failed to express this product on the cell surface, fibroblasts cotransfected with the PIR-A and FcRγc constructs expressed readily detectable PIR-A on the cell surface (Fig. 3 A). The apparent requirement of FcRγc for cell surface expression of PIR-A molecules was examined further by the analysis of FcRγc chain–deficient (FcRγc−/−) mice. While splenocytes from the wild-type mice expressed both PIR-A and PIR-B on the cell surface, only the PIR-B was identified on the cell surface of splenocytes in FcRγc−/− mice (Fig. 3 B). This selective impairment of PIR-A cell surface expression in FcRγc−/− mice was not attributable to a lack of PIR-A production, since the 6C1 mAb identified both the 85-kD PIR-A and the 120-kD PIR-B molecules within FcRγc−/− splenocytes. Therefore, these findings indicate that FcRγc chains are required for the cell surface expression of PIR-A molecules.

Immunofluorescence Analysis of the Cellular Distribution of PIR Expression. When bone marrow cells from adult BALB/c mice were incubated first with aggregated human IgG to block FcγR, then stained with a combination of PE-labeled 6C1 anti-PIR and FITC-, CY-, allophycocyanin-, or biotin-labeled (and CY-labeled streptavidin) mAbs with the following specificity: Mac-1 and Gr-1 for myeloid lineage cells (first row); CD43 and B220 antigens for pro-B/pre-B cell compartment (second row); CD19 and IgM for B lineage cells (third row); CD3 and DX5 for T and NK cells and CD19 or Mac-1 for B cells and macrophages (fourth row); B220, CD21, and CD23 for marginal zone (MZ), follicular (FO), and newly formed (NF) B cells (fifth row); CD19, CD5, and Mac-1 for B1 and B2 subpopulations (sixth row). Staining of cells with light scatter characteristics of myeloid cells or small lymphoid and larger mononuclear cells was analyzed by flow cytometry. In the bottom two rows, B220+ or CD19+ B cells were examined for expression of the indicated cell surface antigens. The cell populations indicated by boxes in contour plots were examined for their expression of PIR molecules (solid line) versus background staining with an isotype-matched control mAb (dashed line). MFI indicates mean fluorescence intensity.

Figure 4. Immunofluorescence analysis of cell surface PIR expression. Bone marrow (BM), spleen (SP), and peritoneal lavage (PEC) cells from adult BALB/c mice were incubated first with aggregated human IgG to block FcγR, then stained with a combination of PE-labeled 6C1 anti-PIR and FITC-, CY-, allophycocyanin-, or biotin-labeled (and CY-labeled streptavidin) mAbs with the following specificity: Mac-1 and Gr-1 for myeloid lineage cells (first row); CD43 and B220 antigens for pro-B/pre-B cell compartment (second row); CD19 and IgM for B lineage cells (third row); CD3 and DX5 for T and NK cells and CD19 or Mac-1 for B cells and macrophages (fourth row); B220, CD21, and CD23 for marginal zone (MZ), follicular (FO), and newly formed (NF) B cells (fifth row); CD19, CD5, and Mac-1 for B1 and B2 subpopulations (sixth row). Staining of cells with light scatter characteristics of myeloid cells or small lymphoid and larger mononuclear cells was analyzed by flow cytometry. In the bottom two rows, B220+ or CD19+ B cells were examined for expression of the indicated cell surface antigens. The cell populations indicated by boxes in contour plots were examined for their expression of PIR molecules (solid line) versus background staining with an isotype-matched control mAb (dashed line). MFI indicates mean fluorescence intensity.
expression with progression of granulocyte differentiation. The B-lineage cells in bone marrow expressed PIR at lower levels relative to the myeloid cells, and most of the PIR + B-lineage cells (CD19+) were IgM+B cells; pro-B were PIR negative while pre-B cells were found to express PIR at lower levels (Fig. 4, second and third rows), indicating a gradual increase in PIR expression as a function of B-lineage differentiation. Bone marrow–derived, IL-3–induced mast cells (c-kit+) also expressed PIR on their cell surface. PIR proteins were not detected on erythroid lineage cells (Ter119+) in the bone marrow. CD3+ thymocytes from newborn and adult BALB/c mice were PIR negative. In striking contrast, marginal zone B cells (B220+CD21low/CD23+), like thymic dendritic cells, were found to express high PIR levels in highly variable levels. When subpopulations of splenic B cells were evaluated, the marginal zone B cells (B220+, CD21high, CD23low−) were found to express higher PIR levels than newly formed (B220+, CD21−, CD23−) and follicular B cells (B220+, CD21med, CD23+) (Fig. 4, fourth row). Moreover, the B1 subpopulations of B cells in peritoneal lavage expressed higher levels of PIR than did the B2 cells (Fig. 4, sixth row). Consistent with this suggestive evidence that B cell activation may enhance PIR expression, cell surface levels of PIR were upregulated by ∼33% after LPS stimulation of splenic B cells, and macrophage PIR expression was similarly enhanced by LPS stimulation. Splenic dendritic cells (MHC class II+, CD11c+, CD19−, Mac-1−, CD8−/−, FcγRI/III−) like thymic dendritic cells, were found to express relatively low to relatively high levels of PIR (Fig. 5).

Cell Surface Expression Levels of PIR-B in FcγR−/− mice. Since cell surface expression of PIR-A was selectively impaired in FcγR−/− deficient mice, PIR-B expression relative to total PIR-A/PIR-B expression could be estimated by immunofluorescence comparison of the cells from FcγR−/− deficient and wild-type mice. Cell surface PIR-B expression alone was thereby found to increase in the FcγR−/− deficient mice as a function of both myeloid and B lineage differentiation (Fig. 6).

Discussion

The monoclonal and polyclonal anti-PIR-A/PIR-B antibodies described here define the cell surface PIR-A and PIR-B receptors as glycoproteins of ∼85 and ∼120 kD, respectively. The ∼120-kD estimate for PIR-B agrees with that obtained using a rabbit antiserum against a p91/PIR-B cytoplasmic peptide (2). In the present studies, the coordinate or paired expression of PIR-A and PIR-B by B and myeloid cells suggested by transcriptional analysis (1) was confirmed by demonstration of both molecules on representative clonal cell lines. Given the finding of splice variants among PIR-A cDNAs (1), we anticipated considerable size heterogeneity of the PIR-A proteins. Contrary to this expectation, the cell surface PIR-A and PIR-B receptors were relatively homogeneous in size, and the predominant protein species were physically indistinguishable in different cell types (B cells versus macrophages) and cell sources (cell lines versus splenocytes). The products of splice variant PIR-A cDNAs thus appear to comprise only a minor fraction of the total PIR-A pool. The PIR-A and PIR-B cDNA sequences indicate an additional free Cys residue in their ectodomains (1), thus suggesting the possible existence of disulfide-linked dimers of the PIR-A and PIR-B molecules. However, disulfide linkage of these molecules was not evident in either one- or two-dimensional gel electrophoresis analyses. It is still theoretically possible that cell surface PIR-A and PIR-B molecules could form noncovalent associations with functional consequence.

Intriguingly, the anti-PIR mAb recognized the PIR-B cell surface receptor on PIR-B transfectants, whereas PIR-A cell surface molecules could not be detected on PIR-A1 producing transfectants. This finding implied the require-

![Thymus](image)

**Figure 5.** PIR expression by thymic and splenic dendritic cells (Top) Thy-1+ T and B220+ B cells were depleted from thymic cell suspensions by complement-mediated lysis, and the remaining cells were stained with the indicated mAbs. The CD11c+/CD19− cells, which comprised ∼1% of the initial MNC population, were analyzed for the expression of PIR and other cell surface markers (MHC class I−/−, Mac-1−, CD8−, and FcγRI/III−). (Bottom) Splenocytes were stained similarly, and the CD11c−/CD19− cells analyzed for other cell surface antigens.
ment for additional membrane-bound protein(s) for PIR-A cell surface expression, a possibility that was also suggested by the presence of a charged Arg residue in the transmembrane region of the predicted PIR-A1 protein (1). There are well documented precedents for the noncovalent association of Ig-like receptor chains containing such charged transmembrane regions with another membrane-bound protein for cell surface expression and/or function. These include (a) the association of ligand-binding \( \alpha \) chain of several Fc receptors (FceR, FcyRI, FcyRIII, Fc\( \alpha \)R) with signal transducing subunits (\( \beta \), \( \gamma \), or \( \zeta \)); (b) the TCR/CD3 complexes; and (c) the killer activating receptor/dendritic

associated protein-12 or killer activating receptor associating protein complexes (20, 26–38). In these examples, the associated proteins typically contain ITAMs in their cytoplasmic domains (31, 39–42). Our immunoprecipitation analysis indicated that the ITAM-containing FcR\( \gamma \)c is associated with PIR molecules present on the cell surface. The implication that the FcR\( \gamma \)c is essential for PIR-A cell surface expression was confirmed in fibroblast cotransfection studies and by the selective expression of PIR-B molecules on B cells and myeloid cells in FcR\( \gamma \)c-deficient mice. In studies reported since submission of this manuscript, a cell activation for the PIR-A/FcR\( \gamma \)c complex has been demonstrated in rat mast cell line and chicken B cell line transfected with constructs for chimeric proteins containing the PIR-A transmembrane and cytoplasmic regions (43, 44).

The restricted expression of PIR molecules by B and myeloid lineage cells indicated by our immunofluorescence analysis is consistent with previous analyses of PIR-A and PIR-B transcripts (1, 2). Cell surface PIR expression was found to increase as a function of cellular differentiation in both cell lineages, indicating that the PIR family is primarily involved in mature cell function. The levels of PIR-A/ PIR-B expression by splenic B cells were remarkably variable. Examination of the different splenic subpopulations indicated that the expression levels were highest on marginal zone B cells, which appear to be primed cells (45). Correspondingly, the B1 subpopulations of B cells expressed higher PIR levels than did the B2 subpopulation. The suggestion that activated B cells may express higher PIR levels was supported by the observation that LPS stimulation enhanced B cell and myeloid cell expression of the PIR molecules, in keeping with the presence of potential binding sites for the LPS- or IL-6-dependent DNA-binding protein in the promoter region of the Pirb gene (15).

In addition to B cells and myeloid lineage cells, the dendritic cells in the thymus and spleen, defined as MHC class II\(^+\) CD11c\(^+\) CD8\(^+/−\) CD4\(^−\) CD19\(^−\) Mac-1\(^−\), were also found to express the PIR molecules on their surface. This finding suggests that the variable PIR-A molecules and invariant PIR-B molecules could be involved in self/non-self discrimination or antigen presentation. The human Ig-like ILT/LIR/MIR receptors, which share 50–60% sequence similarity with mouse PIR, are also expressed by B cells, monocyte/macrophages, and dendritic cells, but, unlike the murine PIR molecules, these human relatives may also be expressed by N K cells and a subpopulation of T cells (9, 11, 46). Some members of the human ILT/LIR/MIR family have been shown to bind classical or nonclassical MHC class I alleles (10, 46–48). Although the ligand or ligands for the PIR molecules are presently unknown, their pattern of expression on myeloid, lymphoid, and dendritic cells suggests that, like other Ig-like cell surface receptors, they may coligate with other activation/inhibitory systems to modulate inflammatory and immune responses. In this regard, these results suggest that the PIR-A requirement for FcR\( \gamma \)c association could result in differential regulation of the PIR-A/PIR-B equilibrium as a function of cellular activation or differentiation pathway.

Figure 6. PIR expression in FcR\( \gamma \)c-deficient and wild-type mice. Bone marrow cells from FcR\( \gamma \)c-deficient (thick line) and wild-type mice (thin line) were stained with 6C1 anti-PIR or control (dotted line) mAb, and the stained cells were analyzed as described in the legend for Fig. 4. Only the wild-type mice control staining is illustrated.
We thank Drs. Peter D. Burrows and Chen-lo Chen for helpful discussion and suggestions. Dr. Suzanne M. Michalek for providing rats, and Marsha Flurry and E. Ann Brookshire for editorial assistance.

This work was supported in part by National Institute of Allergy and Infectious Disease grants AI42127 (H. Kubagawa), AI39816 (M.D. Cooper) and AI34662 (J.V. Ravetch). M.D. Cooper is an investigator of the Howard Hughes Medical Institute.

Address correspondence to H. Kubagawa, 378 W T1, Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294-3300; Phone: 205-934-3370; Fax: 205-975-7218; E-mail: hkubagawa@ccc.uab.edu

Received for publication 31 August 1998 and in revised form 2 November 1998.

References


